PENTAX has identified therapeutic endoscopy devices as a priority for its new investment. Creo will be able to expand PENTAX’s footprint in the therapeutics market.
“We welcome new investor, PENTAX Medical, who has identified endoscopic therapeutic devices as a priority area, and supports our vision to be leaders in electrosurgery. With this investment we are well positioned to complete U.S. regulatory approval, build on our growing intellectual property portfolio and develop commercial traction in key global markets,” said Creo CEO Craig Gulliford.
More articles on gastroenterology:
Dr. Ashley Canipe joins Indian River Medical Center
IBD market to grow at 3.95% until 2019: 5 trends to note
3 recent transactions in the GI field
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.